Abstract
Many epidemiological studies have indicated that Lp (a) is a potent risk factor for coronary heart disease. We have reported the elevation of Lp (a) in NIDDM, especially in subjects with nephropathy, and suggested a possible role for Lp (a) in the development of nephropathy. Herein, we investigated fluctuations in serum Lp (a) concentration induced by metabolic control, and assessed the effectiveness of niceritrol (750mg/day) therapy for hyperlipidemic NIDDM. Our findings were as follows.
1) In diabetics under stable metabolic control, Lp (a) concentration is stable over a several-month interval.
2) Neither significant amelioration or deterioration of glycemic control were associated with significant changes in Lp (a) concentration.
3) Niceritrol therapy resulted in significant decreases in Lp (a) concentrations and might be reduce the risk of diabetic vascular complications.
